| Evaluation of high-pressure retrograde coronary venous delivery of FGF-2 protein. | |
| | |
MedLine Citation:
|
PMID: 14988909 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Delivery of angiogenic factors to ischemic myocardium remains a practical challenge. We evaluated the efficiency and efficacy of delivery of fibroblast growth factor-2 (FGF-2) protein via high-pressure retrograde injection into the anterior interventricular vein (AIV) in a porcine model of chronic myocardial ischemia. Labeled FGF-2 protein was delivered to the myocardium of three pigs via the AIV and the left anterior descending (LAD) coronary artery in three others. At 1 hr, the amount of protein in the left ventricle and the LAD region was quantified. Copper stents were implanted in the LAD of 25 pigs, resulting in chronic myocardial ischemia. At 4 weeks, microsphere-derived myocardial blood flow was assessed at rest and during pacing. In eight pigs (AIV FGF), FGF-2 protein (6 microg/kg) was delivered via high-pressure retrograde injection into the AIV. Six pigs (intracoronary FGF) received the same amount of FGF-2 by intracoronary delivery. Five pigs (AIV saline) received a placebo injection into the AIV and six pigs (control) served as controls. Four weeks later, myocardial blood flow was reassessed. At 1 hr, significantly more FGF remained in the left ventricle (1.3 vs. 0.82 microg; P < 0.04) and in the LAD region (1.2 vs. 0.64 microg; P = 0.03) after AIV compared to intracoronary delivery. Four weeks after treatment, resting LAD blood flow (normalized to right ventricular flow) improved slightly in the AIV FGF and intracoronary FGF arms (1.32-1.37 for both; P = 0.11), while it decreased significantly in the AIV saline (1.32-1.23; P = 0.02) and the control arms (1.32-1.19; P = 0.0004). Pacing LAD blood flow decreased significantly in the control arm (1.30-1.23; P < 0.05), but did not change significantly in the other three arms. High-pressure retrograde injection into the AIV may represent an efficient and effective means for delivering angiogenic factors to ischemic myocardium. |
| | |
Authors:
|
William F Fearon; Fumiaki Ikeno; Lynn R Bailey; Bonnie L Hiatt; Niall A Herity; Andrew J Carter; Peter J Fitzgerald; Mehrdad Rezaee; Alan C Yeung; Paul G Yock |
Related Documents
:
|
9019539 - Extracellular k(+)-induced hyperpolarizations and dilatations of rat coronary and cereb... 6733869 - The effect of coronary inflow pressure on coronary vascular resistance in the isolated ... 3409509 - Effects of perfluorochemical hemodilution on coronary blood flow distribution in dogs. 2456169 - No reflow and extent of infarction during maximal vasodilation in the porcine heart. 9633919 - Ineffective perfusion-contraction matching in conscious, chronically instrumented pigs ... 6602599 - A technique for cardioplegic infusion and left heart venting during coronary artery byp... 2857059 - Beta blockers with intrinsic sympathomimetic activity. 15721729 - Constant positive airway pressure reduces hypoventilation induced by inhalation anesthe... 2459579 - In vivo voltammetry in the b3 group of serotonin neurons of the rat medulla oblongata a... |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions Volume: 61 ISSN: 1522-1946 ISO Abbreviation: Catheter Cardiovasc Interv Publication Date: 2004 Mar |
Date Detail:
|
Created Date: 2004-02-27 Completed Date: 2004-06-25 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 100884139 Medline TA: Catheter Cardiovasc Interv Country: United States |
Other Details:
|
Languages: eng Pagination: 422-8 Citation Subset: IM |
Copyright Information:
|
Copyright 2004 Wiley-Liss, Inc. |
Affiliation:
|
Division of Cardiovascular Medicine, Stanford University Medical Center, Stanford, California 94305, USA. wfearon@stanford.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Coronary Circulation Coronary Vessels Fibroblast Growth Factor 2 / administration & dosage*, pharmacokinetics, therapeutic use Injections, Intra-Arterial Injections, Intravenous Lutetium / diagnostic use Myocardial Ischemia / drug therapy* Myocardium / metabolism Stents Swine |
| Chemical | |
Reg. No./Substance:
|
103107-01-3/Fibroblast Growth Factor 2; 7439-94-3/Lutetium |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A constricting band: an unusual cause of incomplete expansion of Amplatzer septal occluder device.
Next Document: Determining the orientations of ice crystals using electron backscatter patterns.